[Zhifei Bio: Supplementary Application for Influenza Virus Split Vaccine Accepted] On September 4th, Zhifei Bio (300122.SZ) announced that the supplementary application for the influenza virus split vaccine independently developed by Zhifei Longkoma, a wholly-owned subsidiary of the company, has been accepted by the State Food and Drug Administration, and it plans to add "children aged 6-35 months" to the approved population of 3 years old and above. The vaccine has been approved for marketing in September 2025. If it goes well, it will expand the applicable population and form a full age group coverage with the company's existing influenza vaccine products, strengthening market competitiveness. This supplementary application will have no significant impact on recent performance, and subsequent procedures such as technical review are subject to uncertainty.